BSI-201 Demonstrates Significant Tumor Growth Inhibition And Increased Survival Rates In Preclinical Ovarian Cancer Studies BiPar Sciences, Inc. announced positive preclinical data demonstrating the activity of its lead poly ADP-ribose polymerase (PARP) inhibitor, BSI-201, in ovarian cancer models. The results highlight the anti-tumor activity of BSI-201 through PARP activity inhibition, tumor growth suppression, and extended survival in multi-drug resistant xenograft models of ovarian cancer.
Source: www.medicalnewstoday.com
# posted by Network @ 3:00 AM
